These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 16223000)

  • 1. [Comparative evaluation of proliferative activity of breast tumors of different estrogen-progesterone receptor status].
    Ellinidi VN; Anikeeva NV; Goncharova OA; Krasnozhon DA
    Vopr Onkol; 2005; 51(2):197-9. PubMed ID: 16223000
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunohistochemical analysis of retinoic acid receptor-alpha in human breast tumors: retinoic acid receptor-alpha expression correlates with proliferative activity.
    van der Leede BM; Geertzema J; Vroom TM; Décimo D; Lutz Y; van der Saag PT; van der Burg B
    Am J Pathol; 1996 Jun; 148(6):1905-14. PubMed ID: 8669476
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preoperative assessment of proliferative activity and hormonal receptor status in carcinoma of the breast: a comparison of needle aspiration and needle-core biopsies to the surgical specimen.
    Railo M; Nordling S; Krogerus L; Sioris T; von Smitten K
    Diagn Cytopathol; 1996 Sep; 15(3):205-10. PubMed ID: 8955602
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical, histopathologic, and immunohistochemical features of microglandular adenosis and transition into in situ and invasive carcinoma.
    Khalifeh IM; Albarracin C; Diaz LK; Symmans FW; Edgerton ME; Hwang RF; Sneige N
    Am J Surg Pathol; 2008 Apr; 32(4):544-52. PubMed ID: 18300793
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor growth fraction, expression of estrogen and progesterone receptors, p53, bcl-2 and cathepsin D activity in primary ductal invasive breast carcinoma and their axillary lymph node metastases.
    Kristek J; Dmitrović B; Kurbel S; Sakić K; Krajinović Z; Blazicević V; Has B; Marjanović K
    Coll Antropol; 2007 Dec; 31(4):1043-7. PubMed ID: 18217456
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improving outcomes for patients with hormone receptor-positive breast cancer: back to the drawing board.
    Ellis MJ
    J Natl Cancer Inst; 2008 Feb; 100(3):159-61. PubMed ID: 18230793
    [No Abstract]   [Full Text] [Related]  

  • 7. Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group.
    Viale G; Regan MM; Maiorano E; Mastropasqua MG; Golouh R; Perin T; Brown RW; Kovács A; Pillay K; Ohlschlegel C; Braye S; Grigolato P; Rusca T; Gelber RD; Castiglione-Gertsch M; Price KN; Goldhirsch A; Gusterson BA; Coates AS
    J Clin Oncol; 2008 Mar; 26(9):1404-10. PubMed ID: 18349391
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Re-evaluating adjuvant breast cancer trials: assessing hormone receptor status by immunohistochemical versus extraction assays.
    Regan MM; Viale G; Mastropasqua MG; Maiorano E; Golouh R; Carbone A; Brown B; Suurküla M; Langman G; Mazzucchelli L; Braye S; Grigolato P; Gelber RD; Castiglione-Gertsch M; Price KN; Coates AS; Goldhirsch A; Gusterson B;
    J Natl Cancer Inst; 2006 Nov; 98(21):1571-81. PubMed ID: 17077359
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cyclin D1 expression is associated with poor prognostic features in estrogen receptor positive breast cancer.
    Aaltonen K; Amini RM; Landberg G; Eerola H; Aittomäki K; Heikkilä P; Nevanlinna H; Blomqvist C
    Breast Cancer Res Treat; 2009 Jan; 113(1):75-82. PubMed ID: 18240019
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is immunohistochemistry less sensitive than quantitative reverse transcriptase polymerase chain reaction for hormone receptor status determination in breast cancer?
    Arnould L; Coudert B; Fumoleau P
    J Clin Oncol; 2009 Jun; 27(16):2733; author reply 2734-5. PubMed ID: 19380432
    [No Abstract]   [Full Text] [Related]  

  • 11. Menstrual cycle and hormone receptor status in breast cancer patients.
    Atalay C; Kanliöz M; Altinok M
    Neoplasma; 2002; 49(4):278. PubMed ID: 12382029
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PLC-beta2 is highly expressed in breast cancer and is associated with a poor outcome: a study on tissue microarrays.
    Bertagnolo V; Benedusi M; Querzoli P; Pedriali M; Magri E; Brugnoli F; Capitani S
    Int J Oncol; 2006 Apr; 28(4):863-72. PubMed ID: 16525635
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Estrogen insensitivity in a model of estrogen receptor positive breast cancer lymph node metastasis.
    Harrell JC; Dye WW; Harvell DM; Pinto M; Jedlicka P; Sartorius CA; Horwitz KB
    Cancer Res; 2007 Nov; 67(21):10582-91. PubMed ID: 17975003
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic implications of HER-2 status in steroid receptor-positive, lymph node-negative breast carcinoma.
    Peiró G; Adrover E; Aranda FI; Peiró FM; Niveiro M; Sánchez-Payá J
    Am J Clin Pathol; 2007 May; 127(5):780-6. PubMed ID: 17439837
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
    Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
    BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Making breast cancer molecular subtypes robust?
    Staaf J; Ringnér M
    J Natl Cancer Inst; 2015 Jan; 107(1):386. PubMed ID: 25479803
    [No Abstract]   [Full Text] [Related]  

  • 17. Immunohistochemical analysis of 1,25-dihydroxyvitamin-D3-receptors, estrogen and progesterone receptors and Ki-67 in ovarian carcinoma.
    Villena-Heinsen C; Meyberg R; Axt-Fliedner R; Reitnauer K; Reichrath J; Friedrich M
    Anticancer Res; 2002; 22(4):2261-7. PubMed ID: 12174912
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Associations between serum testosterone levels, cell proliferation and progesterone receptor content in normal and malignant breast tissue in postmenopausal women.
    Hofling M; Löfgren L; von Schoultz E; Carlström K; Söderqvist G
    Gynecol Endocrinol; 2008 Jul; 24(7):405-10. PubMed ID: 18645713
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lower level of MAPK expression is associated with anthracycline resistance and decreased survival in patients with hormone receptor negative breast cancer.
    Derin D; Eralp Y; Ozluk Y; Yavuz E; Guney N; Saip P; Igci A; Ozmen V; Kücücük S; Aslay I; Aydiner A; Topuz E
    Cancer Invest; 2008 Aug; 26(7):671-9. PubMed ID: 18608215
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group.
    Kyndi M; Sørensen FB; Knudsen H; Overgaard M; Nielsen HM; Overgaard J;
    J Clin Oncol; 2008 Mar; 26(9):1419-26. PubMed ID: 18285604
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.